Hasty Briefsbeta

Bilingual

An interactome-based framework for DDB1- and CUL4-associated factor prioritization in targeted protein degradation - PubMed
6 days ago
- Developed an interactome-based framework for prioritizing DCAF family proteins in targeted protein degradation.
- Used proximity biotinylation in HEK293T cells to systematically map interactors and functions of DCAFs.
- Identified substrates for model DCAFs COP1 and DCAF3 via multi-omics approaches.
- Proposed CRL4 complex formation and DCAF autodegradation as indicators of DCAF degradation activity.
- Provided a resource for characterizing DCAFs and guiding their use in therapeutic degradation strategies.
New approach methodologies for drug discovery - PubMed
6 days ago
- Traditional animal-based drug discovery has high failure rates, leading to the adoption of human-centered new approach methodologies (NAMs).
- Advances in stem cell-, organoid-, and in silico-based NAMs are supported by evolving NIH and FDA frameworks, covering disease modeling, drug design, and efficacy testing.
- Progress includes identifying therapeutic candidates, developing advanced models and technologies, and using NAMs as potential treatments in preclinical and clinical contexts.
- Key bottlenecks in biology, technology, and regulation must be addressed for robust translational adoption of NAMs.
- Translational and societal considerations are essential for responsible NAM adoption, with future human-centric pipelines set to redefine drug discovery.
Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings - PubMed
6 days ago
- A 39-year-old man with severe long COVID symptoms, including cognitive dysfunction and fatigue, received high-dose intravenous immunoglobulin (IVIG) therapy.
- Treatment involved initial and maintenance IVIG doses over several cycles, leading to normalization of fatigue scores, neurocognitive recovery, and improved quality of life within a year.
- Immunological changes observed included a persistent inverted CD4 to CD8 T-cell ratio and a reduction in CD8+ T cell-monocyte complexes, IFNγ/TNF production, endothelial inflammation markers, and autoantibody titers.
- The case suggests IVIG may modulate post-viral immune dysregulation in long COVID, warranting further evaluation as a potential therapeutic approach in selected patients.
Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis - PubMed
6 days ago
- Patient navigation and mailed FIT outreach are the most effective interventions for increasing colorectal cancer screening uptake.
- Educational multimedia and reminder-only interventions show modest effects, while choice-based and colonoscopy outreach are not significantly better than usual care.
- In low baseline uptake settings (<30%), mailed FIT outreach is especially effective, whereas educational multimedia performs better in higher uptake populations and recent studies.
- The analysis included 76 randomized trials, with most evidence rated moderate to low certainty.
Metabolic and inflammatory roles of glial cells in neurodegenerative and cerebrovascular diseases - PubMed
6 days ago
- Chronic neuroinflammation, driven by microglia and astrocytes, is central to neurodegenerative and cerebrovascular diseases.
- Single-cell studies show glial heterogeneity; microglia shift to glycolysis, releasing cytokines and ROS, while astrocytes accumulate toxic lipids, amplifying inflammation.
- Key pathways like NF-κB, NLRP3, and C3/C3aR foster glial activation and detrimental feedback loops, worsened by cholesterol issues, vesicle communication, and mitochondrial dysfunction.
- The review highlights gaps in understanding context-specific interactions and discusses treatments targeting glial metabolism and immune signaling to slow disease progression.
SERCA2 dysfunction drives vascular calcification via coupling with TSPO-MCU at mitochondria-associated endoplasmic reticulum membranes - PubMed
6 days ago
- SERCA2 dysfunction, marked by oxidized Cys674, is elevated in calcified arteries of mice and CKD patients.
- SERCA2 dysfunction worsens vascular calcification, mitochondrial impairment, and calcium overload in VSMCs.
- The mechanism involves increased MAM formation, with TSPO coupling SERCA2 to the IP3R1-Grp75-VDAC1-MCU complex.
- TSPO knockdown alleviates calcification in SERCA2 dysfunction models, while TSPO overexpression aggravates it.
- Inhibiting MCU reduces mitochondrial calcium overload and mitigates calcification effects.
Eosinophilic Versus Non-Eosinophilic Acute Exacerbations of COPD and Subsequent Cardiovascular Event - PubMed
6 days ago
- Eosinophilic acute exacerbations of COPD (AE-COPD) were associated with a lower one-year risk of major adverse cardiovascular events (MACE) compared to non-eosinophilic AE-COPD.
- The study analyzed 143,517 patients, with 33,761 classified as eosinophilic AE-COPD (blood eosinophil count ≥300/μL) and 109,756 as non-eosinophilic.
- After propensity score matching, the hazard ratio (HR) for MACE was 1.22 for non-eosinophilic AE-COPD vs. eosinophilic AE-COPD, indicating a 22% higher risk in the non-eosinophilic group.
- Eosinophilic AE-COPD also showed reduced risks of specific cardiovascular events like heart failure, acute myocardial infarction, stroke, arrhythmia, and lower all-cause mortality.
- The findings were robust across sensitivity analyses, suggesting blood eosinophil count at exacerbation could help stratify long-term cardiovascular risk in COPD patients.
Anaphylaxis Guidelines - PubMed
6 days ago
- Compares 12 national and international anaphylaxis guidelines from 2006 to 2025.
- Highlights evolving methodological frameworks, diagnostic criteria, and treatment approaches.
- Consensus supports prompt epinephrine use, but differences exist in definitions and post-acute care.
- Identifies gaps in education, early childhood care protocols, and global harmonization.
- Emphasizes shift from crisis-based to proactive management and need for equity-focused, evidence-based interventions.
Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy - PubMed
6 days ago
- High PAR-2 activation in cancer patient serum correlates with worse survival after immunotherapy.
- Inhibiting PAR-2 genetically or pharmacologically boosts anti-PD-1 therapy in preclinical models.
- PAR-2 blockade reduces immunosuppressive myeloid cells and enhances CD8+ T cell activation.
- PAR-2 inhibition shifts cytokines toward Th1-type responses and away from immunosuppression.
- Myeloid cell RNA sequencing shows PAR-2 impairs antigen presentation pathways.
- Ex vivo, PAR-2 inhibition improves antigen presentation by CD11c+ dendritic cells.
- PAR-2 targeting is a promising strategy to overcome resistance to immune checkpoint inhibitors.
Associations between respiratory diseases and lung cancer risk: a secondary analysis of the large-scale prospective UK biobank cohort - PubMed
6 days ago
- Respiratory diseases are associated with increased lung cancer risk (HR 2.97).
- Acute respiratory infections show strong associations with lung cancer incidence, especially viral pneumonia (HR 9.86).
- Squamous cell carcinoma exhibits the highest risk elevation among subtypes (HR 3.65).
- Neutrophil counts partially mediate the associations (up to 8% mediated).
- Study uses UK Biobank cohort data with 2189 lung cancer cases over mean 10.44-year follow-up.
Effects of socioeconomic status on adverse pregnancy outcomes: a Mendelian randomisation and mediation analysis - PubMed
6 days ago
- Higher educational level was found to be causally linked to reduced risks of several adverse pregnancy outcomes, including gestational diabetes, gestational hypertension, and pre-eclampsia.
- Body mass index (BMI) mediated a significant portion (50.8-60.3%) of the associations between education level and gestational diabetes, gestational hypertension, and pre-eclampsia.
- Cigarette consumption mediated 28.1% of the association with ectopic pregnancy, and alcohol intake frequency explained 42.1% of the link with gestational hypertension.
- The study used Mendelian randomization to establish causal relationships, suggesting socioeconomic disadvantage, particularly lower education, directly impacts pregnancy outcomes through modifiable factors.
Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer - PubMed
6 days ago
- FXR1 is amplified and overexpressed in ovarian and other cancers, regulating oncogene translation.
- LNA-modified siRNA (siFXR1-LNA) enhances stability, uptake, and inhibits tumor growth, ascites, and metastasis more effectively than native siRNA.
- silencing FXR1 suppresses tumor cell proliferation and reduces M2-like macrophages while boosting anti-tumor immune cells like cytotoxic T cells, NK cells, and dendritic cells.
- FXR1 is identified as a key therapeutic target for siRNA-based treatment in ovarian cancer.
Social reward outcompetes drug seeking dopaminergic ensembles to prevent relapse - PubMed
6 days ago
- Drugs of abuse hijack mesolimbic circuits that process natural rewards.
- Social reward has therapeutic potential for substance use disorder (SUD).
- Two distinct dopaminergic ensembles in the VTA encode social reward and drug seeking.
- These antagonistic ensembles compete reciprocally to shape behavioral outcomes.
- Social reward-responsive dopaminergic ensembles receive preferential input from the dorsal raphe nucleus (DRN).
- Activation of the DRN-VTA pathway mimics social reward's protective effects against drug seeking.
- Social reward attenuates drug seeking through dynamic competition between dopaminergic ensembles.
Non-canonical IL‑22 receptor signaling remodels the oral mucosal barrier during Candida albicans immunosurveillance - PubMed
6 days ago
- Fungal-induced immunosurveillance enhances resistance to Candida albicans outgrowth and invasion by remodeling the oral mucosal epithelial barrier in mouse models.
- Epithelial remodeling depends on IL-22 and STAT3 signaling via a non-canonical receptor complex of gp130, IL-22Rα1, and IL-10Rβ.
- Epithelial proliferation boosts antifungal defenses by upregulating antimicrobial peptide expression.
- This immunosurveillance-induced epithelial remodeling is specific to the oral mucosa and resets once fungal-specific immunity develops.
- The study identifies transient mucosal remodeling as a key factor in resisting mucosal fungal infection during early colonization.
A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome - PubMed
6 days ago
- A kidney-targeted nanocarrier (T-PAAD NPs) is developed for site-specific inhibition of SGLT2 to treat cardiovascular-kidney-metabolic (CKM) syndrome.
- The nanocarrier releases empagliflozin (EMPA) selectively in renal tubules in response to high urea levels, improving renal specificity and reducing systemic side effects.
- It combines reactive oxygen species (ROS) scavenging with drug delivery to mitigate oxidative stress and enhance therapeutic outcomes.
- In mouse models of CKM, T-PAAD NPs/EMPA outperformed free EMPA, improving glycemic control, renal function, and cardiovascular health.
- This bioresponsive platform offers a promising strategy for treating systemic metabolic disorders by integrating targeted drug release with metabolic modulation.
S100A6 promotes liver metastasis by activating FGFR3 signaling in BAP1-deficient uveal melanoma - PubMed
6 days ago
- S100A6 is consistently upregulated in BAP1-deficient uveal melanoma, promoting liver metastasis.
- BAP1 deficiency leads to increased H2AK119ub and Pol II recruitment at the S100A6 promoter, enhancing its transcription.
- S100A6 acts as a novel ligand for FGFR3, activating distinct signaling and inflammatory cancer-associated fibroblasts.
- Targeting the S100A6-FGFR3 pathway suppresses metastasis in preclinical models, showing therapeutic promise.
Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease - PubMed
6 days ago
- The article discusses the urgent need for target product profiles (TPPs) for therapies aimed at delaying or preventing symptomatic Alzheimer's disease, due to the absence of approved preventive treatments despite scientific advances.
- An international expert group convened by the Global CEO Initiative on Alzheimer's Disease developed TPPs that outline minimum and preferred characteristics for these therapies, including intended use, target populations, safety, and efficacy benchmarks.
- Multiple candidate interventions are currently in clinical trials for at-risk individuals or those with elevated biomarkers but no symptoms, with data expected within 1-2 years, highlighting the importance of stakeholder alignment on therapy characteristics.
- The TPPs provide a foundational framework to accelerate therapeutic development and guide researchers, regulators, and patients in evaluating emerging preventive therapies for Alzheimer's disease.
Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer's disease pathogenesis - PubMed
6 days ago
- APOE4 is the strongest genetic risk factor for Alzheimer's disease (AD), but its early impact on neuronal and network function is unclear.
- Young APOE4 knockin mice show hippocampal network hyperexcitability, which predicts later cognitive deficits and originates from specific subpopulations of smaller, hyperexcitable neurons.
- Removing neuronal APOE4 eliminates this early hyperexcitability, indicating a direct role of APOE4 in neuronal dysfunction.
- Aged APOE4 knockin mice develop further excitability issues, including granule cell hyperexcitability and progressive inhibitory dysfunction in the dentate gyrus.
- Single-nucleus RNA sequencing identifies age-dependent transcriptional changes and Nell2 as a candidate mediator of early hyperexcitability.
- CRISPR interference knockdown of Nell2 rescues abnormal excitability, confirming its role in APOE4-driven dysfunction.
- The study links neuronal APOE4-induced early network impairment to AD pathogenesis through molecular and circuit mechanisms.
Recent advances in CAR T and CAR NK cell therapy for AML - PubMed
6 days ago
- CAR T cell therapy has shown significant success in treating B-cell lymphomas, B-cell leukemias, and multiple myeloma, but is urgently needed for acute myeloid leukemia (AML).
- A major challenge in CAR T therapy for AML is identifying AML-specific antigens, as candidates like CD33, CD123, and CLL-1 are also expressed on normal hematopoietic cells, risking bone marrow aplasia and on-target/off-tumor toxicity.
- CAR NK cell therapy is a promising alternative for AML due to its lower toxicity, off-the-shelf availability, reduced risk of graft-versus-host disease (GVHD), and potentially milder cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
- The review covers the current status of CAR T and CAR NK cell development for AML and introduces a new therapy targeting mismatched HLA-DRB1 for AML patients who relapsed after allogeneic hematopoietic stem cell transplant.
Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial - PubMed
6 days ago
- Seladelpar improved pruritus severity and distribution in patients with primary biliary cholangitis (PBC) and pruritus.
- Itch-related sleep disturbance was consistently improved with seladelpar treatment across patient populations.
- Seladelpar improved measures of fatigue compared to placebo in patients with severe itch at baseline.
- Patients without itching tended to remain free from itching with seladelpar, with fewer adverse events of pruritus.
- Seladelpar is a potent and selective PPARδ agonist showing anticholestatic effects and quality-of-life benefits in PBC.

first prev24next

About|Login

Bilingual

An interactome-based framework for DDB1- and CUL4-associated factor prioritization in targeted protein degradation - PubMed
6 days ago
- Developed an interactome-based framework for prioritizing DCAF family proteins in targeted protein degradation.
- Used proximity biotinylation in HEK293T cells to systematically map interactors and functions of DCAFs.
- Identified substrates for model DCAFs COP1 and DCAF3 via multi-omics approaches.
- Proposed CRL4 complex formation and DCAF autodegradation as indicators of DCAF degradation activity.
- Provided a resource for characterizing DCAFs and guiding their use in therapeutic degradation strategies.
New approach methodologies for drug discovery - PubMed
6 days ago
- Traditional animal-based drug discovery has high failure rates, leading to the adoption of human-centered new approach methodologies (NAMs).
- Advances in stem cell-, organoid-, and in silico-based NAMs are supported by evolving NIH and FDA frameworks, covering disease modeling, drug design, and efficacy testing.
- Progress includes identifying therapeutic candidates, developing advanced models and technologies, and using NAMs as potential treatments in preclinical and clinical contexts.
- Key bottlenecks in biology, technology, and regulation must be addressed for robust translational adoption of NAMs.
- Translational and societal considerations are essential for responsible NAM adoption, with future human-centric pipelines set to redefine drug discovery.
Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings - PubMed
6 days ago
- A 39-year-old man with severe long COVID symptoms, including cognitive dysfunction and fatigue, received high-dose intravenous immunoglobulin (IVIG) therapy.
- Treatment involved initial and maintenance IVIG doses over several cycles, leading to normalization of fatigue scores, neurocognitive recovery, and improved quality of life within a year.
- Immunological changes observed included a persistent inverted CD4 to CD8 T-cell ratio and a reduction in CD8+ T cell-monocyte complexes, IFNγ/TNF production, endothelial inflammation markers, and autoantibody titers.
- The case suggests IVIG may modulate post-viral immune dysregulation in long COVID, warranting further evaluation as a potential therapeutic approach in selected patients.
Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis - PubMed
6 days ago
- Patient navigation and mailed FIT outreach are the most effective interventions for increasing colorectal cancer screening uptake.
- Educational multimedia and reminder-only interventions show modest effects, while choice-based and colonoscopy outreach are not significantly better than usual care.
- In low baseline uptake settings (<30%), mailed FIT outreach is especially effective, whereas educational multimedia performs better in higher uptake populations and recent studies.
- The analysis included 76 randomized trials, with most evidence rated moderate to low certainty.
Metabolic and inflammatory roles of glial cells in neurodegenerative and cerebrovascular diseases - PubMed
6 days ago
- Chronic neuroinflammation, driven by microglia and astrocytes, is central to neurodegenerative and cerebrovascular diseases.
- Single-cell studies show glial heterogeneity; microglia shift to glycolysis, releasing cytokines and ROS, while astrocytes accumulate toxic lipids, amplifying inflammation.
- Key pathways like NF-κB, NLRP3, and C3/C3aR foster glial activation and detrimental feedback loops, worsened by cholesterol issues, vesicle communication, and mitochondrial dysfunction.
- The review highlights gaps in understanding context-specific interactions and discusses treatments targeting glial metabolism and immune signaling to slow disease progression.
SERCA2 dysfunction drives vascular calcification via coupling with TSPO-MCU at mitochondria-associated endoplasmic reticulum membranes - PubMed
6 days ago
- SERCA2 dysfunction, marked by oxidized Cys674, is elevated in calcified arteries of mice and CKD patients.
- SERCA2 dysfunction worsens vascular calcification, mitochondrial impairment, and calcium overload in VSMCs.
- The mechanism involves increased MAM formation, with TSPO coupling SERCA2 to the IP3R1-Grp75-VDAC1-MCU complex.
- TSPO knockdown alleviates calcification in SERCA2 dysfunction models, while TSPO overexpression aggravates it.
- Inhibiting MCU reduces mitochondrial calcium overload and mitigates calcification effects.
Eosinophilic Versus Non-Eosinophilic Acute Exacerbations of COPD and Subsequent Cardiovascular Event - PubMed
6 days ago
- Eosinophilic acute exacerbations of COPD (AE-COPD) were associated with a lower one-year risk of major adverse cardiovascular events (MACE) compared to non-eosinophilic AE-COPD.
- The study analyzed 143,517 patients, with 33,761 classified as eosinophilic AE-COPD (blood eosinophil count ≥300/μL) and 109,756 as non-eosinophilic.
- After propensity score matching, the hazard ratio (HR) for MACE was 1.22 for non-eosinophilic AE-COPD vs. eosinophilic AE-COPD, indicating a 22% higher risk in the non-eosinophilic group.
- Eosinophilic AE-COPD also showed reduced risks of specific cardiovascular events like heart failure, acute myocardial infarction, stroke, arrhythmia, and lower all-cause mortality.
- The findings were robust across sensitivity analyses, suggesting blood eosinophil count at exacerbation could help stratify long-term cardiovascular risk in COPD patients.
Anaphylaxis Guidelines - PubMed
6 days ago
- Compares 12 national and international anaphylaxis guidelines from 2006 to 2025.
- Highlights evolving methodological frameworks, diagnostic criteria, and treatment approaches.
- Consensus supports prompt epinephrine use, but differences exist in definitions and post-acute care.
- Identifies gaps in education, early childhood care protocols, and global harmonization.
- Emphasizes shift from crisis-based to proactive management and need for equity-focused, evidence-based interventions.
Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy - PubMed
6 days ago
- High PAR-2 activation in cancer patient serum correlates with worse survival after immunotherapy.
- Inhibiting PAR-2 genetically or pharmacologically boosts anti-PD-1 therapy in preclinical models.
- PAR-2 blockade reduces immunosuppressive myeloid cells and enhances CD8+ T cell activation.
- PAR-2 inhibition shifts cytokines toward Th1-type responses and away from immunosuppression.
- Myeloid cell RNA sequencing shows PAR-2 impairs antigen presentation pathways.
- Ex vivo, PAR-2 inhibition improves antigen presentation by CD11c+ dendritic cells.
- PAR-2 targeting is a promising strategy to overcome resistance to immune checkpoint inhibitors.
Associations between respiratory diseases and lung cancer risk: a secondary analysis of the large-scale prospective UK biobank cohort - PubMed
6 days ago
- Respiratory diseases are associated with increased lung cancer risk (HR 2.97).
- Acute respiratory infections show strong associations with lung cancer incidence, especially viral pneumonia (HR 9.86).
- Squamous cell carcinoma exhibits the highest risk elevation among subtypes (HR 3.65).
- Neutrophil counts partially mediate the associations (up to 8% mediated).
- Study uses UK Biobank cohort data with 2189 lung cancer cases over mean 10.44-year follow-up.
Effects of socioeconomic status on adverse pregnancy outcomes: a Mendelian randomisation and mediation analysis - PubMed
6 days ago
- Higher educational level was found to be causally linked to reduced risks of several adverse pregnancy outcomes, including gestational diabetes, gestational hypertension, and pre-eclampsia.
- Body mass index (BMI) mediated a significant portion (50.8-60.3%) of the associations between education level and gestational diabetes, gestational hypertension, and pre-eclampsia.
- Cigarette consumption mediated 28.1% of the association with ectopic pregnancy, and alcohol intake frequency explained 42.1% of the link with gestational hypertension.
- The study used Mendelian randomization to establish causal relationships, suggesting socioeconomic disadvantage, particularly lower education, directly impacts pregnancy outcomes through modifiable factors.
Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer - PubMed
6 days ago
- FXR1 is amplified and overexpressed in ovarian and other cancers, regulating oncogene translation.
- LNA-modified siRNA (siFXR1-LNA) enhances stability, uptake, and inhibits tumor growth, ascites, and metastasis more effectively than native siRNA.
- silencing FXR1 suppresses tumor cell proliferation and reduces M2-like macrophages while boosting anti-tumor immune cells like cytotoxic T cells, NK cells, and dendritic cells.
- FXR1 is identified as a key therapeutic target for siRNA-based treatment in ovarian cancer.
Social reward outcompetes drug seeking dopaminergic ensembles to prevent relapse - PubMed
6 days ago
- Drugs of abuse hijack mesolimbic circuits that process natural rewards.
- Social reward has therapeutic potential for substance use disorder (SUD).
- Two distinct dopaminergic ensembles in the VTA encode social reward and drug seeking.
- These antagonistic ensembles compete reciprocally to shape behavioral outcomes.
- Social reward-responsive dopaminergic ensembles receive preferential input from the dorsal raphe nucleus (DRN).
- Activation of the DRN-VTA pathway mimics social reward's protective effects against drug seeking.
- Social reward attenuates drug seeking through dynamic competition between dopaminergic ensembles.
Non-canonical IL‑22 receptor signaling remodels the oral mucosal barrier during Candida albicans immunosurveillance - PubMed
6 days ago
- Fungal-induced immunosurveillance enhances resistance to Candida albicans outgrowth and invasion by remodeling the oral mucosal epithelial barrier in mouse models.
- Epithelial remodeling depends on IL-22 and STAT3 signaling via a non-canonical receptor complex of gp130, IL-22Rα1, and IL-10Rβ.
- Epithelial proliferation boosts antifungal defenses by upregulating antimicrobial peptide expression.
- This immunosurveillance-induced epithelial remodeling is specific to the oral mucosa and resets once fungal-specific immunity develops.
- The study identifies transient mucosal remodeling as a key factor in resisting mucosal fungal infection during early colonization.
A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome - PubMed
6 days ago
- A kidney-targeted nanocarrier (T-PAAD NPs) is developed for site-specific inhibition of SGLT2 to treat cardiovascular-kidney-metabolic (CKM) syndrome.
- The nanocarrier releases empagliflozin (EMPA) selectively in renal tubules in response to high urea levels, improving renal specificity and reducing systemic side effects.
- It combines reactive oxygen species (ROS) scavenging with drug delivery to mitigate oxidative stress and enhance therapeutic outcomes.
- In mouse models of CKM, T-PAAD NPs/EMPA outperformed free EMPA, improving glycemic control, renal function, and cardiovascular health.
- This bioresponsive platform offers a promising strategy for treating systemic metabolic disorders by integrating targeted drug release with metabolic modulation.
S100A6 promotes liver metastasis by activating FGFR3 signaling in BAP1-deficient uveal melanoma - PubMed
6 days ago
- S100A6 is consistently upregulated in BAP1-deficient uveal melanoma, promoting liver metastasis.
- BAP1 deficiency leads to increased H2AK119ub and Pol II recruitment at the S100A6 promoter, enhancing its transcription.
- S100A6 acts as a novel ligand for FGFR3, activating distinct signaling and inflammatory cancer-associated fibroblasts.
- Targeting the S100A6-FGFR3 pathway suppresses metastasis in preclinical models, showing therapeutic promise.
Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease - PubMed
6 days ago
- The article discusses the urgent need for target product profiles (TPPs) for therapies aimed at delaying or preventing symptomatic Alzheimer's disease, due to the absence of approved preventive treatments despite scientific advances.
- An international expert group convened by the Global CEO Initiative on Alzheimer's Disease developed TPPs that outline minimum and preferred characteristics for these therapies, including intended use, target populations, safety, and efficacy benchmarks.
- Multiple candidate interventions are currently in clinical trials for at-risk individuals or those with elevated biomarkers but no symptoms, with data expected within 1-2 years, highlighting the importance of stakeholder alignment on therapy characteristics.
- The TPPs provide a foundational framework to accelerate therapeutic development and guide researchers, regulators, and patients in evaluating emerging preventive therapies for Alzheimer's disease.
Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer's disease pathogenesis - PubMed
6 days ago
- APOE4 is the strongest genetic risk factor for Alzheimer's disease (AD), but its early impact on neuronal and network function is unclear.
- Young APOE4 knockin mice show hippocampal network hyperexcitability, which predicts later cognitive deficits and originates from specific subpopulations of smaller, hyperexcitable neurons.
- Removing neuronal APOE4 eliminates this early hyperexcitability, indicating a direct role of APOE4 in neuronal dysfunction.
- Aged APOE4 knockin mice develop further excitability issues, including granule cell hyperexcitability and progressive inhibitory dysfunction in the dentate gyrus.
- Single-nucleus RNA sequencing identifies age-dependent transcriptional changes and Nell2 as a candidate mediator of early hyperexcitability.
- CRISPR interference knockdown of Nell2 rescues abnormal excitability, confirming its role in APOE4-driven dysfunction.
- The study links neuronal APOE4-induced early network impairment to AD pathogenesis through molecular and circuit mechanisms.
Recent advances in CAR T and CAR NK cell therapy for AML - PubMed
6 days ago
- CAR T cell therapy has shown significant success in treating B-cell lymphomas, B-cell leukemias, and multiple myeloma, but is urgently needed for acute myeloid leukemia (AML).
- A major challenge in CAR T therapy for AML is identifying AML-specific antigens, as candidates like CD33, CD123, and CLL-1 are also expressed on normal hematopoietic cells, risking bone marrow aplasia and on-target/off-tumor toxicity.
- CAR NK cell therapy is a promising alternative for AML due to its lower toxicity, off-the-shelf availability, reduced risk of graft-versus-host disease (GVHD), and potentially milder cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
- The review covers the current status of CAR T and CAR NK cell development for AML and introduces a new therapy targeting mismatched HLA-DRB1 for AML patients who relapsed after allogeneic hematopoietic stem cell transplant.
Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial - PubMed
6 days ago
- Seladelpar improved pruritus severity and distribution in patients with primary biliary cholangitis (PBC) and pruritus.
- Itch-related sleep disturbance was consistently improved with seladelpar treatment across patient populations.
- Seladelpar improved measures of fatigue compared to placebo in patients with severe itch at baseline.
- Patients without itching tended to remain free from itching with seladelpar, with fewer adverse events of pruritus.
- Seladelpar is a potent and selective PPARδ agonist showing anticholestatic effects and quality-of-life benefits in PBC.

Hasty Briefsbeta

An interactome-based framework for DDB1- and CUL4-associated factor prioritization in targeted protein degradation - PubMed

New approach methodologies for drug discovery - PubMed

Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings - PubMed

Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis - PubMed

Metabolic and inflammatory roles of glial cells in neurodegenerative and cerebrovascular diseases - PubMed

SERCA2 dysfunction drives vascular calcification via coupling with TSPO-MCU at mitochondria-associated endoplasmic reticulum membranes - PubMed

Eosinophilic Versus Non-Eosinophilic Acute Exacerbations of COPD and Subsequent Cardiovascular Event - PubMed

Anaphylaxis Guidelines - PubMed

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy - PubMed

Associations between respiratory diseases and lung cancer risk: a secondary analysis of the large-scale prospective UK biobank cohort - PubMed

Effects of socioeconomic status on adverse pregnancy outcomes: a Mendelian randomisation and mediation analysis - PubMed

Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer - PubMed

Social reward outcompetes drug seeking dopaminergic ensembles to prevent relapse - PubMed

Non-canonical IL‑22 receptor signaling remodels the oral mucosal barrier during Candida albicans immunosurveillance - PubMed

A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome - PubMed

S100A6 promotes liver metastasis by activating FGFR3 signaling in BAP1-deficient uveal melanoma - PubMed

Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease - PubMed

Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer's disease pathogenesis - PubMed

Recent advances in CAR T and CAR NK cell therapy for AML - PubMed

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial - PubMed

An interactome-based framework for DDB1- and CUL4-associated factor prioritization in targeted protein degradation - PubMed

New approach methodologies for drug discovery - PubMed

Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings - PubMed

Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis - PubMed

Metabolic and inflammatory roles of glial cells in neurodegenerative and cerebrovascular diseases - PubMed

SERCA2 dysfunction drives vascular calcification via coupling with TSPO-MCU at mitochondria-associated endoplasmic reticulum membranes - PubMed

Eosinophilic Versus Non-Eosinophilic Acute Exacerbations of COPD and Subsequent Cardiovascular Event - PubMed

Anaphylaxis Guidelines - PubMed

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy - PubMed

Associations between respiratory diseases and lung cancer risk: a secondary analysis of the large-scale prospective UK biobank cohort - PubMed

Effects of socioeconomic status on adverse pregnancy outcomes: a Mendelian randomisation and mediation analysis - PubMed

Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer - PubMed

Social reward outcompetes drug seeking dopaminergic ensembles to prevent relapse - PubMed

Non-canonical IL‑22 receptor signaling remodels the oral mucosal barrier during Candida albicans immunosurveillance - PubMed

A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome - PubMed

S100A6 promotes liver metastasis by activating FGFR3 signaling in BAP1-deficient uveal melanoma - PubMed

Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease - PubMed

Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer's disease pathogenesis - PubMed

Recent advances in CAR T and CAR NK cell therapy for AML - PubMed

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial - PubMed